Showing results (11-20 of 411) with videos related to
Sort By:
Pageof 42
The Oncologist|July 31, 2016
Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based AnalysisAdam J Olszewski, Steven P Treon, Jorge J CastilloCancer Treatment and Research|February 7, 2015
Biology, prognosis, and therapy of Waldenström MacroglobulinemiaJorge J Castillo, Irene M Ghobrial, Steven P TreonCancer Journal (Sudbury, Mass.)|February 4, 2016
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative DisordersJorge J Castillo, Steven P Treon, Matthew S DavidsTherapeutic Advances in Hematology|August 6, 2016
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceJorge J Castillo, M Lia Palomba, Ranjana Advani, et al.Leukemia & Lymphoma|February 11, 2021
Clinical application of genomics in Waldenström macroglobulinemiaAndrew R Branagan, Mathew Lei, Steven P Treon, et al.Hematology/Oncology Clinics of North America|September 13, 2014
Waldenström macroglobulinemiaSteven P Treon, Zachary R Hunter, Jorge J Castillo, et al.Expert Review of Hematology|June 16, 2017
Novel approaches to targeting MYD88 in Waldenström macroglobulinemiaJorge J Castillo, Zachary R Hunter, Guang Yang, et al.American Journal of Hematology|November 23, 2022
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemiaJorge J Castillo, Christian Buske, Judith Trotman, et al.Expert Review of Anticancer Therapy|April 11, 2022
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemiaShayna Sarosiek, David Sermer, Andrew R Branagan, et al.Clinical Lymphoma, Myeloma & Leukemia|March 27, 2022
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström MacroglobulinemiaDavid Sermer, Shayna Sarosiek, Andrew R Branagan, et al.Pageof 42